|
Hepatitis C Virus and Vaccine Development
|
Malihe Naderi   1, Naghmeh Gholipour2 , Mohammad Reza Zolfaghari3 , Binabaj Maryam Moradi4 , Ahmad Yegane Moghadam5 , Motalleb Gholamreza6 |
1- Department of Microbiology, Qom branch, Islamic Azad University, Qom, Iran. , rezamotalleb@gmail.com
2- National Institute of Genetic Engineering and Biotechnology, Department of Molecular Genetics, Tehran, Iran.
3- Department of Microbiology, Qom branch, Islamic Azad University, Qom, Iran.
4- Department of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran.
5- Kashan University of Medical Sciences, Department of Otolaryngology, Kashan, Iran.
6- Faculty of Science, Department of Biology, University of Zabol, Zabol, Iran. |
|
|
Abstract: (10454 Views) |
| The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical use. DNA vaccines have some advantages such as producing feasibility and generating intensive cellular and humoral immune responses. Activation and improvement of natural immune defense mechanisms is a necessity for the development of an effective HCV vaccine. This article discusses the current status of therapies for hepatitis C, the promising new therapies and the experimental strategies to develop an HCV vaccine. |
|
| Keywords: HCV, DNA vaccine, IFN- α, cellular immune response |
|
|
Full-Text [PDF 183 kb]
(3466 Downloads)
|
Type of Study: Original Article |
Subject:
Infectious disease (Molecular and Cellular aspects)
Received: 2014/05/23 | Accepted: 2014/08/2 | Published: 2014/09/10
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
